Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results. Zelensky agrees to US minerals deal after Trump rows back demands ...

CEO David Endicott highlighted 2024 as a strong year for Alcon, with annual sales reaching $9.8 billion, a 6% increase, and core diluted EPS growing by 16% to $3.05. Free cash flow hit a record $1 ...

Reports Q4 revenue $2.48B, consensus $2.47B. “In 2024, our unwavering focus on innovation and operational excellence delivered another set of ...

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments ...